PMID- 24077952
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20211021
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 33
IP  - 4
DP  - 2014 Apr
TI  - Anti-apolipoprotein A-1 antibodies and carotid intima-media thickness in Egyptian 
      women with systemic lupus erythematosus.
PG  - 493-8
AB  - The objective of the study was to evaluate anti-apolipoprotein A-I (Apo A-I) and 
      carotid intima-media thickness (cIMT) as cardiovascular risk factors in Egyptian 
      women with systemic lupus erythematosus (SLE). The study included 160 subjects, 
      80 women with SLE and 80 healthy women as a control group. Disease activity score 
      (SLEDAI), disease damage index (SLICC/ACR), lipid profile, complement C3 and C4, 
      high-sensitivity CRP (hsCRP), anti-dsDNA and anticardiolipin antibodies were 
      evaluated in addition to anti-Apo A-I antibodies and cIMT. The mean age of 
      patients was 28.35 +/- 7.06 years with mean disease duration of 4.58 +/- 3.36 years. 
      Anti-Apo A-I antibody titer was significantly higher in SLE patients than in 
      controls (mean 35.3 +/- 6.8 vs. 21.4 +/- 5.91 U/L; P = 0.000). Carotid ultrasound 
      showed significantly thickened intima in SLE patients compared with control 
      subjects (mean thickness, 0.5 +/- 0.08 vs. 0.45 +/- 0.06 mm; P = 0.003). Correlation 
      studies with other cardiovascular risk factors demonstrated significant 
      associations between anti-Apo A-I and SLEDAI, SLICC/ACR, C3 and C4. On the other 
      hand, cIMT showed significant association with age, systolic blood pressure, 
      hsCRP and body mass index. Thus, SLE disease activity is associated with a 
      significant increase in anti-Apo A-I titer. Also, increased cIMT might be a 
      cardiovascular risk factor in Egyptian patients with SLE.
FAU - Radwan, M M
AU  - Radwan MM
AD  - 1Department of Internal Medicine, National Research Centre, Cairo, Egypt
FAU - El-Lebedy, D
AU  - El-Lebedy D
FAU - Fouda, R
AU  - Fouda R
FAU - Elsorougy, E
AU  - Elsorougy E
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Cardiolipins)
RN  - 0 (Complement C3)
RN  - 0 (Complement C4)
RN  - 0 (Lipids)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Age Factors
MH  - Antibodies, Anti-Idiotypic/*blood
MH  - Apolipoprotein A-I/*immunology
MH  - Body Mass Index
MH  - C-Reactive Protein/analysis
MH  - Cardiolipins/immunology
MH  - *Carotid Intima-Media Thickness
MH  - Case-Control Studies
MH  - Complement C3/analysis
MH  - Complement C4/analysis
MH  - DNA/immunology
MH  - Egypt
MH  - Female
MH  - Humans
MH  - Lipids/blood
MH  - Lupus Erythematosus, Systemic/blood/*diagnostic imaging/drug therapy/*immunology
MH  - Risk Factors
EDAT- 2013/10/01 06:00
MHDA- 2015/12/15 06:00
CRDT- 2013/10/01 06:00
PHST- 2013/06/10 00:00 [received]
PHST- 2013/09/17 00:00 [accepted]
PHST- 2013/07/23 00:00 [revised]
PHST- 2013/10/01 06:00 [entrez]
PHST- 2013/10/01 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1007/s10067-013-2399-8 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2014 Apr;33(4):493-8. doi: 10.1007/s10067-013-2399-8.